Mounjaro is a once-weekly injectable medicine that contains tirzepatide. Doctors prescribe it to improve blood sugar control in people with type 2 diabetes, and the label now also lists a heart-protection use. Mounjaro acts on two gut hormone pathways instead of one, which sets it apart from older GLP-1 medicines. This guide explains what the current U.S. label says about uses, dosing patterns, side effects, birth control, and safety.
The facts below come mainly from the current Mounjaro prescribing information on the FDA website (revised August 2026). Labels change over time, so check the newest version and the Medication Guide that comes with your prescription.
What Is Mounjaro?
Mounjaro is a brand-name prescription medicine from Eli Lilly, first approved in the United States in 2022. Its active ingredient, tirzepatide, activates two receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1). Both receptors respond to hormones that your gut releases after you eat. The label gives tirzepatide’s half-life as about five days, which supports one injection per week.
You need a prescription. Mounjaro is not sold over the counter, and the label tells doctors to use it alongside diet and exercise rather than in place of them.
Mounjaro and Zepbound
Tirzepatide is also sold under the brand name Zepbound, which the manufacturer markets for weight management. The two brands have separate labels, so details differ. This article covers only Mounjaro.
What Is Mounjaro Used For?
According to the current label, Mounjaro is approved for:
- Blood sugar control. It improves glycemic control, with diet and exercise, in adults and in children aged 10 and older with type 2 diabetes.
- Heart protection. It lowers the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events. Lilly added this use to the label in August 2026.
Weight loss is not a listed use of Mounjaro, although weight often falls during treatment. In the label’s trials, adults on Mounjaro lost an average of about 6 to 11 kg (roughly 14 to 25 lb), depending on the dose and the trial, compared with small changes on placebo. Those results describe average trial groups, not what any one person will experience.
How Does Mounjaro Work?
Tirzepatide boosts the body’s own insulin release after meals and lowers glucagon, a hormone that raises blood sugar. Both effects depend on your glucose level, so they fade when blood sugar is normal. The label also says tirzepatide lowers fasting and after-meal glucose, reduces food intake, and reduces body weight. It increases insulin sensitivity as well.
It slows stomach emptying, too. The slowing is strongest after the first dose and fades over time. That effect explains some stomach-related side effects, and it matters for pills, anesthesia, and birth control (covered below).
Mounjaro Forms and Strengths
The label lists several presentations, and each has its own instructions for use:
- Single-dose pen or single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 0.5 mL.
- Multi-dose vial: four weekly doses in 2.4 mL. You draw each dose into a syringe.
- KwikPen: a single-patient-use pen that holds four fixed weekly doses.
Check the carton every time you pick up a refill. The strength and presentation can change, and you should receive training for the exact one you get.
How to Use Mounjaro Safely
Dosing Basics
Your prescriber chooses your dose. For general understanding, the label describes this pattern:
- The starting dose is 2.5 mg injected once a week.
- If more blood sugar control is needed, the prescriber can raise the dose in 2.5 mg steps, with at least four weeks on each dose.
- The maximum dose is 15 mg once weekly for adults and 10 mg once weekly for children.
Do not use this list to set your own dose. The slow step-up exists to reduce stomach side effects.
Injecting Mounjaro
- Inject once a week at any time of day, with or without food.
- Inject under the skin of the abdomen or thigh. Another person can inject into the back of your upper arm.
- Rotate the injection site each week.
- Look at the liquid first. It should be colorless to slightly yellow, without particles or cloudiness. Do not use it if it was frozen.
- If you use insulin too, give separate injections and never mix them. You may inject both in the same body area, but not next to each other.
- Never share a KwikPen or needles with anyone, even if you change the needle.
People who are blind or have vision problems should not use the KwikPen without help from a trained person, and children should not self-inject with it. The KwikPen needs priming before every injection, and you must throw it away after four weekly doses, even if liquid remains.
What to Do If You Miss a Dose
Take the missed dose as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip it and take your next dose on the regular day. Never take two doses within 3 days of each other. You may change your weekly injection day if at least 3 days (72 hours) separate the two doses.
Common Side Effects of Mounjaro
Stomach and digestive problems are the most common side effects. In placebo-controlled trials in adults with type 2 diabetes, these side effects each affected at least 5% of people on Mounjaro:
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Dyspepsia (indigestion) | 3% | 8% | 8% | 5% |
| Abdominal pain | 4% | 6% | 5% | 5% |
Overall, digestive reactions affected 20.4% of people on placebo and 37% to 44% of people on Mounjaro, depending on dose. The label says most nausea, vomiting, and diarrhea happened during dose increases and eased over time. Between 3% and 6.6% of people stopped Mounjaro because of digestive effects, compared with 0.4% on placebo.
Other reported effects include injection site reactions (3.2% versus 0.4% on placebo), a small rise in resting heart rate (an average of 2 to 4 beats per minute), unusual skin sensations called dysesthesia, and a changed sense of taste. After approval, people also reported hair loss. Children had more vomiting, abdominal pain, and low blood sugar than adults in their trial.
Serious Side Effects and Warnings
Boxed Warning: Thyroid C-Cell Tumors
Mounjaro carries the FDA’s strongest warning. In rats, tirzepatide caused thyroid C-cell tumors. No one knows whether it causes these tumors, including a rare cancer called medullary thyroid carcinoma (MTC), in people. Do not use Mounjaro if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a neck lump, trouble swallowing, shortness of breath, or lasting hoarseness.
Other Important Warnings
- Pancreatitis. Severe, persistent stomach pain, sometimes spreading to the back, calls for stopping the medicine and getting help right away.
- Low blood sugar. The risk rises when you combine Mounjaro with insulin or a sulfonylurea (a type of diabetes pill). Your prescriber may lower those doses.
- Serious allergic reactions. Swelling of the face, lips, tongue, or throat, trouble breathing, or severe rash needs emergency care.
- Kidney injury. Vomiting and diarrhea can dehydrate you and injure the kidneys. Some people needed dialysis.
- Severe stomach problems. The label does not recommend Mounjaro in people with severe gastroparesis (very slow stomach emptying). Reports after approval include bowel blockage and severe constipation.
- Diabetic eye disease. Rapid improvement in blood sugar can temporarily worsen retinopathy. People with a history of it need monitoring.
- Gallbladder disease. Gallstones and related problems appeared in 0.6% of Mounjaro users and 0% of placebo users in trials.
- Anesthesia and sedation. Slower stomach emptying can leave food in the stomach even after fasting, and stomach contents can reach the lungs during anesthesia or deep sedation. Tell every surgeon, dentist, and anesthesia provider that you use Mounjaro.
Who Should Avoid Mounjaro or Use Caution?
The label lists two contraindications: a personal or family history of MTC or MEN 2, and a known serious allergic reaction to tirzepatide or any ingredient. Tell your prescriber before you start if you have had pancreas problems, severe stomach or digestion problems, diabetic eye disease, or a planned procedure that uses anesthesia or deep sedation.
Safety and effectiveness are established in children aged 10 and older with type 2 diabetes, but not in younger children. The label found no overall differences in safety or effectiveness in adults 65 and older. It recommends no dose change for kidney or liver impairment, although it advises monitoring kidney function in people with kidney problems who have severe stomach side effects.
Mounjaro, Birth Control, and Other Drug Interactions
Mounjaro can reduce how well birth control pills work. Because it slows stomach emptying, it can lower absorption of the pill’s hormones. In a study, a single 5 mg dose reduced peak levels of the pill’s hormones by 55% to 66%. The label tells people who use oral hormonal contraceptives to switch to a non-oral method or add a barrier method (such as condoms) for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. Hormonal contraceptives that are not taken by mouth should not be affected.
The slower emptying can also affect other pills. The label advises monitoring people who take oral medicines that depend on reaching a threshold level, or that have a narrow safety margin, such as warfarin. In the label’s study, the first dose lowered peak acetaminophen levels by 50%, but by week 4 the effect was not meaningful. Insulin and sulfonylureas raise the risk of low blood sugar.
Give your pharmacist a full list of your prescriptions, over-the-counter medicines, vitamins, and supplements.
Pregnancy and Breastfeeding
Pregnancy. Human data are insufficient. Animal studies showed possible harm to the fetus, and the label says to use Mounjaro in pregnancy only if the potential benefit justifies the potential risk. Poorly controlled diabetes also carries real risks in pregnancy, so talk with your doctor about the safest plan before you try to conceive. Remember the birth control warning above.
Breastfeeding. In a small study of 11 breastfeeding women, tirzepatide was undetectable or very low in breast milk. No data exist on effects on the baby or on milk production. Discuss the benefits of breastfeeding and your treatment needs with your provider.
How to Store Mounjaro
- Keep it in the original carton, protected from heat and light. Do not freeze it, and do not use it if it froze.
- Single-dose pens and vials: Store in the refrigerator at 36°F to 46°F (2°C to 8°C). If needed, you can keep them unrefrigerated at up to 86°F (30°C) for a total of 21 days, then discard them.
- Multi-dose vials and KwikPens, unopened: Refrigerate. At room temperature, discard unopened products after 30 days.
- Multi-dose vials and KwikPens, in use: Keep in the carton, in the refrigerator or at room temperature up to 86°F. Discard after 30 days at room temperature, 30 days after first use, or after four weekly doses, even if liquid remains.
Counterfeit and Compounded Tirzepatide
Demand for GLP-1 medicines has created a market for unapproved copies. The FDA states that compounded GLP-1 drugs, including tirzepatide products, are not FDA approved, and it has received reports of dosing errors, side effects, and fraudulent products. Use only prescriptions from licensed pharmacies, and report suspicious products to your pharmacist and to the FDA’s MedWatch program.
When to Get Medical Help
Call 911 or go to an emergency room for trouble breathing or swelling of the face, lips, tongue, or throat. Contact a healthcare provider promptly for severe or lasting stomach pain, repeated vomiting or diarrhea, signs of dehydration, a neck lump, vision changes, upper belly pain with fever or yellowing skin, or symptoms of low blood sugar such as shakiness, sweating, confusion, or a fast heartbeat. In case of an overdose, call Poison Help at 1-800-222-1222.
Frequently Asked Questions About Mounjaro
Is Mounjaro approved for weight loss?
No. Mounjaro’s approved uses are type 2 diabetes and heart-risk reduction in certain adults with type 2 diabetes. Tirzepatide for weight management is sold under a different brand, Zepbound.
How does Mounjaro compare with semaglutide?
In a 40-week trial in adults on metformin, people on Mounjaro 5, 10, and 15 mg lowered HbA1c by 2.0, 2.2, and 2.3 percentage points, compared with 1.9 for semaglutide 1 mg. Weight fell by 7.6, 9.3, and 11.2 kg, compared with 5.7 kg. These are group averages, and your own result may differ.
Does Mounjaro lower heart attack and stroke risk?
The label lists this use. In a large trial comparing Mounjaro with dulaglutide (another GLP-1 medicine), Mounjaro was non-inferior, meaning it worked about as well, for the combined outcome of heart death, heart attack, and stroke. The label states that it did not establish superiority to dulaglutide.
Can I use Mounjaro with birth control pills?
You can, but the pill may work less well. The label advises a non-oral method or a barrier method for 4 weeks after you start and 4 weeks after each dose increase. Ask your prescriber which option fits you.
What happens if I stop taking Mounjaro?
Talk with your prescriber first. Your blood sugar plan may need to change. If you stop because you are planning a pregnancy, ask your doctor how to control your diabetes safely during that time.
Can I share a pen with someone who has the same prescription?
Never. Sharing a KwikPen or needles can pass on serious blood-borne infections, even if you change the needle.
References
- Mounjaro (tirzepatide) prescribing information, U.S. FDA (revised 08/2026)
- GLP-1 agonists, MedlinePlus Medical Encyclopedia
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Conclusion
Mounjaro is a once-weekly tirzepatide injection for type 2 diabetes, with a newer approval for lowering heart risk in high-risk adults. It can lower blood sugar and weight substantially, but it carries a boxed warning and real risks, including digestive problems, pancreatitis, dehydration, and gallbladder disease. Use the dose your prescriber sets, plan around the birth control warning, tell every care provider before a procedure, and buy only genuine product from a licensed pharmacy.
Medical Disclaimer
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided is not a substitute for professional medical advice from a qualified healthcare provider. Always consult your doctor or pharmacist before starting, stopping, or changing any medication. Do not disregard professional medical advice or delay seeking it because of information in this article. If you think you are experiencing a medical emergency, seek emergency medical assistance immediately.